EBQ:Single Dose Dexamethasone in Asthma: Difference between revisions

(pdf link)
(study design)
Line 15: Line 15:
}}
}}
==Clinical Question==
==Clinical Question==
What is the efficacy of a single dose of oral dexamethasone as compared with 5 days of twice-daily prednisolone in the treatment of mild to moderate asthma exacerbations in children seen in the emergency department?
How does a of a single dose of oral dexamethasone compare with 5 days of twice-daily prednisolone in the treatment of mild to moderate asthma exacerbations in children seen in the emergency department?


==Conclusion==
==Conclusion==
A single dose of oral dexamethasone (0.6 mg/kg) is no worse than 5 days of twice-daily prednisolone (1 mg/kg per dose) in the management of children with mild to moderate asthma exacerbations.


==Major Points==  
==Major Points==  


==Study Design==
==Study Design==
*Prospective, randomized, double-blinded trial conducted at British Columbia Children's Hospital
*All children presenting to the ED with mild to moderate asthma exacerbations were assessed by the emergency attending physician who decided if the child needed treatment with salbutamol
**Before starting treatment, PIS, vital signs, oxygen saturation, and peak expiratory flow rate (if pt ≥6 years old) were recorded
*Pt reasssesed 20 minutes after first salbutamol, and  if further treatment was needed the patient was consented to study
*All patients received second and third salbutamol 20 minutes apart
**Decision to give more salbutamol after third dose was up to discretion of attending
   
   
==Population==
==Population==
===Patient Demographics===
===Patient Demographics===
===Inclusion Criteria===
===Inclusion Criteria===
*2-16 years old who presented to the ED with acute mild to moderate asthma exacerbation
**Mild to moderate asthma exacerbation defined as a Pulmonary Index Score (PIS) of less than 9 or a PEFR ≥ 60% of predicted value by height
*History of at least 1 prior episode of ‘‘asthma-like’’ acute shortness of breath or wheezing that was treated with salbutamol


===Exclusion Criteria===
===Exclusion Criteria===
*Signs of severe asthma on presentation
**PEFR < 60%, PIS ≥ 10
*Complete recovery after first salbutamol therapy
*Use of oral steroids in the last 2 weeks
*History of severe asthma exacerbation, including prior intubation or ICU admission for asthma
*Chronic lung disease
*Heart disease
*Neurological disorder
*Psychiatric disease
*History of acute allergic reaction
*Active chickenpox or herpes simplex infections


==Interventions==  
==Interventions==  
*Patients received single-dose oral dexamethasone (0.6 mg/kg to a maximum of 18 mg) or oral prednisolone (1 mg/kg per dose to a maximum of 30 mg)
twice daily for 5 days
*Pts were contacted by telephone at 48 hrs to assess symptoms and reevaluated in the ED in 5 days
 
==Outcomes==
==Outcomes==
   
   


===Primary Outcome===
===Primary Outcome===
*Primary outcome was number of days needed for Patient Self Assessment Score to return to baseline (score of 0-0.5)
**Mean was 5.21 vs. 5.22 days (Dex vs. Pred)


===Secondary Outcomes===  
===Secondary Outcomes===  
*Mean time to discharge: 3.5 hours vs. 4.3 hours
*Initial admission rate: 9% vs. 13.4%
*Re-admission rate after initial discharge: 4.9% vs. 1.8%
*Overall hospital admission rate: 13.4% vs. 14.9%
*No significant difference in the number of salbutamol therapies needed in the ED nor at home after discharge


===Subgroup analysis===
===Subgroup analysis===

Revision as of 22:58, 18 September 2015

incomplete Journal Club Article
Altamimi S. et al. "Single-dose oral dexamethasone in the emergency management of children with exacerbations of mild to moderate asthma". Pediatric Emergency Care. 2006. 786-793(22):12.
PubMed Full text PDF

Clinical Question

How does a of a single dose of oral dexamethasone compare with 5 days of twice-daily prednisolone in the treatment of mild to moderate asthma exacerbations in children seen in the emergency department?

Conclusion

A single dose of oral dexamethasone (0.6 mg/kg) is no worse than 5 days of twice-daily prednisolone (1 mg/kg per dose) in the management of children with mild to moderate asthma exacerbations.

Major Points

Study Design

  • Prospective, randomized, double-blinded trial conducted at British Columbia Children's Hospital
  • All children presenting to the ED with mild to moderate asthma exacerbations were assessed by the emergency attending physician who decided if the child needed treatment with salbutamol
    • Before starting treatment, PIS, vital signs, oxygen saturation, and peak expiratory flow rate (if pt ≥6 years old) were recorded
  • Pt reasssesed 20 minutes after first salbutamol, and if further treatment was needed the patient was consented to study
  • All patients received second and third salbutamol 20 minutes apart
    • Decision to give more salbutamol after third dose was up to discretion of attending

Population

Patient Demographics

Inclusion Criteria

  • 2-16 years old who presented to the ED with acute mild to moderate asthma exacerbation
    • Mild to moderate asthma exacerbation defined as a Pulmonary Index Score (PIS) of less than 9 or a PEFR ≥ 60% of predicted value by height
  • History of at least 1 prior episode of ‘‘asthma-like’’ acute shortness of breath or wheezing that was treated with salbutamol

Exclusion Criteria

  • Signs of severe asthma on presentation
    • PEFR < 60%, PIS ≥ 10
  • Complete recovery after first salbutamol therapy
  • Use of oral steroids in the last 2 weeks
  • History of severe asthma exacerbation, including prior intubation or ICU admission for asthma
  • Chronic lung disease
  • Heart disease
  • Neurological disorder
  • Psychiatric disease
  • History of acute allergic reaction
  • Active chickenpox or herpes simplex infections

Interventions

  • Patients received single-dose oral dexamethasone (0.6 mg/kg to a maximum of 18 mg) or oral prednisolone (1 mg/kg per dose to a maximum of 30 mg)

twice daily for 5 days

  • Pts were contacted by telephone at 48 hrs to assess symptoms and reevaluated in the ED in 5 days

Outcomes

Primary Outcome

  • Primary outcome was number of days needed for Patient Self Assessment Score to return to baseline (score of 0-0.5)
    • Mean was 5.21 vs. 5.22 days (Dex vs. Pred)

Secondary Outcomes

  • Mean time to discharge: 3.5 hours vs. 4.3 hours
  • Initial admission rate: 9% vs. 13.4%
  • Re-admission rate after initial discharge: 4.9% vs. 1.8%
  • Overall hospital admission rate: 13.4% vs. 14.9%
  • No significant difference in the number of salbutamol therapies needed in the ED nor at home after discharge

Subgroup analysis

Criticisms & Further Discussion

Funding

Sources